Cencora Inc. Stock Price, News & Analysis

Cencora (NYSE: COR) has announced an agreement to repurchase approximately $50 million worth of its common stock from Walgreens Boots Alliance Holdings The repurchase will coincide with Walgreens Boots Alliance's sale of Cencora shares under Rule 144 of the Securities Act of 1933.

The share repurchase will be executed at a price equal to the Rule 144 sale price, with repurchased shares being held in treasury. This transaction occurs alongside the early settlement of previously disclosed variable prepaid forward sale contracts between Walgreens Boots Alliance and financial institutions.

Walgreens Boots Alliance's remaining Cencora shares continue to be pledged as security for other existing variable prepaid forward sale contracts. Cencora, ranked #10 on the Fortune 500 and #18 on the Global Fortune 500, generates over $290 billion in annual revenue and employs 46,000+ team members globally.

Walgreens Boots Alliance (WBA) has announced the early settlement of certain prepaid variable share forward transactions related to Cencora shares, resulting in approximately $300 million in proceeds. The transaction involves the delivery of 6.1 million Cencora shares and a concurrent sale of 1.3 million additional shares.

Following the settlement, WBA retains approximately 12.6 million Cencora shares pledged under remaining forward contracts, scheduled to mature during March, June, and September 2025. The company's ownership in Cencora has decreased from 10% to approximately 6%. The proceeds will primarily be used for debt paydown, specifically addressing fiscal year 2026 debt maturities, and general corporate purposes.

The transaction includes a net aggregate cash payment of approximately $20 million to financial institutions. Despite the reduced ownership, WBA maintains its strategic partnership with Cencora, with Ornella Barra continuing to serve on Cencora's Board of Directors.

Cencora (NYSE: COR) reported strong financial results for its fiscal 2025 first quarter ended December 31, 2024. The company achieved revenue of $81.5 billion, marking a significant 12.8% increase compared to the same period last year.

The company's GAAP diluted earnings per share (EPS) was $2.50, compared to $2.98 in the prior year's first quarter. However, adjusted diluted EPS, excluding certain items, showed robust growth of 13.7%, reaching $3.73 compared to $3.28 in the previous year.

Following these results, Cencora has raised its adjusted diluted EPS guidance range for fiscal 2025 to $15.25 to $15.55.

Harrow (HROW) has announced a strategic partnership with Cencora (COR) to launch the 'Harrow Cares' program, aimed at improving accessibility and affordability of IHEEZO® and TRIESENCE® for retina specialists and their patients. The program offers comprehensive support services through a state-of-the-art patient support hub.

The initiative includes multiple key features: streamlined enrollment through various channels, real-time benefit verifications for rapid treatment access, flexible affordability options including commercial copay assistance with patients paying as little as $0, and ongoing support services including patient welcome calls and prior authorization denial assistance.

This partnership represents Harrow's strategic focus on expanding its presence in the U.S. retina market and demonstrates the company's commitment to improving healthcare accessibility while driving better patient outcomes.

Cencora (NYSE: COR) has scheduled its First Quarter Fiscal 2025 earnings release for Wednesday, February 5, 2025, before the NYSE opening bell. The company will host a conference call at 8:30 a.m. ET the same day, featuring President & CEO Robert P. Mauch and CFO James F. Cleary.

The earnings call will be accessible via webcast on investor.cencora.com and by telephone. U.S. and Canada participants can dial (833) 470-1428, while international callers should use +1 (404) 975-4839, with access code 427679. Replays will be available on the website and via telephone for 7 days using the access code 402593.

Cencora is a global pharmaceutical solutions organization ranked #10 on the Fortune 500 and #18 on the Global Fortune 500, generating over $290 billion in annual revenue. The company employs 46,000+ team members worldwide.

Cencora (NYSE: COR) has completed its previously announced acquisition of Retina Consultants of America (RCA), acquiring approximately 85% interest in the leading management services organization of retina specialists. The remaining minority equity interest is retained by RCA physicians and management team members.

The transaction involved a cash outlay of $4.4 billion at closing, subject to post-closing price adjustments. This amount includes equity rollover, cash capitalization of RCA, transaction fees, expenses, and debt repayment.

The strategic acquisition strengthens Cencora's specialty leadership position and expands its MSO solutions, aiming to create differentiated value for stakeholders, including physicians and patients. Following the acquisition, Cencora has raised its Adjusted Diluted EPS guidance range to $15.15 to $15.45 for Fiscal 2025.

Cencora (NYSE: COR) has successfully closed a public offering of senior notes totaling $1.8 billion. The offering consists of three tranches: $500 million of 4.625% notes due 2027, $600 million of 4.850% notes due 2029, and $700 million of 5.150% notes due 2035.

The proceeds will be used to finance the acquisition of the majority stake in Retina Consultants of America, related fees, and general corporate purposes. The offering was managed by BofA Securities, Citigroup Global Markets, J.P. Morgan Securities, and Wells Fargo Securities.

Cencora (NYSE: COR) has announced pricing for three senior notes offerings totaling $1.8 billion: $500 million of 4.625% notes due 2027, $600 million of 4.850% notes due 2029, and $700 million of 5.150% notes due 2035. The offering, expected to close on December 9, 2024, will fund the acquisition of Retina Consultants of America's majority stake and general corporate purposes. The offering is managed by BofA Securities, Citigroup Global Markets, J.P. Morgan Securities, and Wells Fargo Securities.

Cencora (NYSE: COR) reported Q4 fiscal 2024 revenue of $79.1 billion, up 14.7% year-over-year, with full-year revenue reaching $294.0 billion, a 12.1% increase. Q4 GAAP diluted EPS was $0.02, while adjusted diluted EPS grew 16.8% to $3.34. For fiscal 2024, GAAP diluted EPS decreased 11.7% to $7.53, while adjusted diluted EPS increased 14.8% to $13.76.

The company increased its quarterly dividend by 8% to $0.55 per share and announced the acquisition of Retina Consultants of America. U.S. Healthcare Solutions revenue grew 15.7% to $71.7 billion, while International Healthcare Solutions revenue increased 5.5% to $7.4 billion in Q4.